Gross evidence for tumor at autopsy in B6 recipients of TCD BMCs plus CD4-depleted spleen cells from WT or GKO BALB/c mice
| Groups . | Tumor at autopsy (no. with tumor/total evaluated) . | |
|---|---|---|
| Exp 1 . | Exp 2 . | |
| Syngeneic BMT + 500 EL4 | 4/4 | 4/4 |
| WT BALB/c BMT + 500 EL4 | 1/7 | 0/7 |
| GKO BALB/c BMT + 500 EL4 | 4/7 | 3/7 |
| Nonleukemic recipients | 0/5 | 0/17 |
| Groups . | Tumor at autopsy (no. with tumor/total evaluated) . | |
|---|---|---|
| Exp 1 . | Exp 2 . | |
| Syngeneic BMT + 500 EL4 | 4/4 | 4/4 |
| WT BALB/c BMT + 500 EL4 | 1/7 | 0/7 |
| GKO BALB/c BMT + 500 EL4 | 4/7 | 3/7 |
| Nonleukemic recipients | 0/5 | 0/17 |
Allogeneic BMT recipient mice were transplanted with 5 × 106 TCD BMCs and 10 × 106 (Exp 1) or 7.5 × 106 (Exp 2) CD4-depleted spleen cells from WT or GKO BALB/c mice. B6 mice receiving 5 × 106 TCD B6 BMCs were used as syngeneic BMT controls. Leukemic recipients were additionally injected with 500 EL4 cells. Nonleukemic controls (nonleukemic recipients) are pooled animals from both syngeneic and allogeneic BMT groups.